# Pharmacokinetics/Pharmacodynamics Biomarker Study in Active Ulcerative Colitis Patients

> **NCT01284062** · PHASE2 · COMPLETED · sponsor: **Pfizer** · enrollment: 84 (actual)

## Conditions studied

- Colitis, Ulcerative

## Interventions

- **BIOLOGICAL:** Anrukinzumab
- **BIOLOGICAL:** Anrukinzumab
- **BIOLOGICAL:** Anrukinzumab
- **OTHER:** placebo

## Key facts

- **NCT ID:** NCT01284062
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-03
- **Primary completion:** 2013-04
- **Final completion:** 2013-04
- **Target enrollment:** 84 (ACTUAL)
- **Last updated:** 2014-11-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01284062

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01284062, "Pharmacokinetics/Pharmacodynamics Biomarker Study in Active Ulcerative Colitis Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01284062. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*